EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions

Yali Wu, Helena Leonie Hanae Loer, Yifan Zhang, Dafang Zhong, Yong Jiang, Jie Hu, Uwe Fuhr iD, Thorsten Lehr iD, Xingxing Diao

CPT: Pharmacometrics & Systems Pharmacology · 2025

DOI: 10.1002/psp4.70052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Yali Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Hauptthemen laut MEDLINE: Models, Biological, Protein Kinase Inhibitors, Pyrimidines. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: China Scholarship Council, National Natural Science Foundation of China, Key Technologies R&D Program of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Furmonertinib demonstrated potent efficacy as a newly developed tyrosine kinase inhibitor for the treatment of patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer. In vitro research showed that furmonertinib is metabolized to its active metabolite AST5902 via the cytochrome P450 (CYP) enzyme CYP3A4. Furmonertinib is a strong CYP3A4 inducer, while the metabolite is a weaker CYP3A4 inducer. In clinical studies, nonlinear pharmacokinetics were observed during chronic dosing. The apparent clearance showed time‐ and dose‐dependent increases. In this evaluation, a combination of in vitro data using radiolabeled compounds, clinical pharmacokinetic data, and drug–drug interaction (DDI) data of furmonertinib in oncology patients and/or in healthy subjects was used to develop a physiologically based pharmacokinetic (PBPK) model. The model was built in PK‐Sim Version 11 using a total of 44 concentration‐time profiles of furmonertinib and its metabolite AST5902. Suitability of the predictive model performance was demonstrated by both goodness‐of‐fit plots and statistical evaluation. The model predicted the observed monotherapy concentration profiles of furmonertinib well, with 32/32 predicted AUC last (area under the curve until the last concentration measurement) values and 32/32 maximum plasma concentration ( C max ) ratios being within twofold of the respective observed values. In addition, 8/8 predicted DDI AUC last and C max ratios with furmonertinib as a victim of CYP3A4 inhibition or induction were within twofold of their respective observed values. Potential applications of the final model include the prediction of DDIs for chronic administration of CYP3A4 perpetrators along with furmonertinib, considering auto‐induction of furmonertinib and its metabolite AST5902.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Models, BiologicalProtein Kinase InhibitorsPyrimidinesHumansDrug InteractionsCytochrome P-450 CYP3AMaleCytochrome P-450 CYP3A InducersFemaleMiddle AgedAdultCarcinoma, Non-Small-Cell LungLung Neoplasms

Substanzen

Cytochrome P-450 CYP3ACYP3A4 protein, humanProtein Kinase InhibitorsCytochrome P-450 CYP3A InducersPyrimidines

Autor:innen und Institutionen

  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Clinical Pharmacology, Department I of Pharmacology, Center for Pharmacology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
  • Clinical Pharmacy, Saarland University, Saarbrücken, Germany.
  • Shanghai Allist Pharmaceuticals Co., Ltd, Shanghai, China.

ORCID-Profile: Uwe Fuhr, Thorsten Lehr

Förderung

  • China Scholarship Council
  • National Natural Science Foundation of China
  • Key Technologies R&D Program of Guangdong Province
  • National Key R&D Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Wu, Y., Loer, H. L. H., Zhang, Y., Zhong, D., Jiang, Y., Hu, J., Fuhr, U., Lehr, T., & Diao, X. (2025). Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70052

Vancouver

Wu Y, Loer HLH, Zhang Y, Zhong D, Jiang Y, Hu J, et al. Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70052

BibTeX
@article{Wu2025,
  author = {Wu, Yali and Loer, Helena Leonie Hanae and Zhang, Yifan and Zhong, Dafang and Jiang, Yong and Hu, Jie and Fuhr, Uwe and Lehr, Thorsten and Diao, Xingxing},
  title = {Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions},
  journal = {CPT: Pharmacometrics & Systems Pharmacology},
  year = {2025},
  doi = {10.1002/psp4.70052}
}
Kostenlos starten →